Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Phase II study of high-dose somatostatin analogue in patients either previously treated or untreated who have extensive-stage small cell lung cancer
Autore:
Marschke, RF; Grill, JP; Sloan, JA; Wender, DB; Levitt, R; Mailliard, JA; Gerstner, JB; Ghosh, C; Morton, RF; Jett, JR;
Indirizzi:
Mayo Clin, CCOP, Scottsdale, AZ USA Mayo Clin Scottsdale AZ USAMayo Clin, CCOP, Scottsdale, AZ USA Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA Mayo Clin & Mayo Fdn Rochester MN USA 55905 Fdn, Rochester, MN 55905 USA Siouxland Hematol Oncol Associates, Sioux City, IA USA Siouxland Hematol Oncol Associates Sioux City IA USA Sioux City, IA USA Meritcare Hosp, Fargo, ND USA Meritcare Hosp Fargo ND USAMeritcare Hosp, Fargo, ND USA Univaha,raska, Creighton Univ, Med Ctr & Associates, Nebraska Oncol Grp, Om Univ Nebraska Omaha NE USA 68182 Ctr & Associates, Nebraska Oncol Grp, Om Illinois Oncol Res Assoc, Peoria, IL USA Illinois Oncol Res Assoc Peoria IL USA s Oncol Res Assoc, Peoria, IL USA Cedar Rapids Oncol Project, Cedar Rapids, IA USA Cedar Rapids Oncol Project Cedar Rapids IA USA ect, Cedar Rapids, IA USA Iowa Oncol Res Assoc CCOP, Des Moines, IA USA Iowa Oncol Res Assoc CCOP Des Moines IA USA soc CCOP, Des Moines, IA USA
Titolo Testata:
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
fascicolo: 1, volume: 22, anno: 1999,
pagine: 15 - 17
SICI:
0277-3732(199902)22:1<15:PISOHS>2.0.ZU;2-L
Fonte:
ISI
Lingua:
ENG
Soggetto:
CARCINOMA; GROWTH; CHEMOTHERAPY; SOMATULINE; ETOPOSIDE; PROGRESS; INVITRO; LINES; GENE;
Keywords:
analogue; somatostatin; stage;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
24
Recensione:
Indirizzi per estratti:
Indirizzo: Marschke, RF Hematol Oncol Associates, 1240 Doctors Lane,Suite 200, Ft Collins, CO 80524 Hematol Oncol Associates 1240 Doctors Lane,Suite 200 Ft Collins CO USA 80524
Citazione:
R.F. Marschke et al., "Phase II study of high-dose somatostatin analogue in patients either previously treated or untreated who have extensive-stage small cell lung cancer", AM J CL ONC, 22(1), 1999, pp. 15-17

Abstract

The authors conducted a phase II study of somatostatin analogue in 18 patients with extensive stage small cell lung cancer (four with previous treatment, 14 without previous treatment). Patients received 2,000 mg subcutaneously thrice daily. They were required to have an Eastern Cooperative Oncology Group performance score of 0-2 and acceptable pretreatment biochemical parameters. No patient responded to treatment. The median time to progressionwas 44 days. The median survival was 106 days. Toxicity related to treatment consisted of mild diarrhea and anorexia. Somatostatin analogue is not active as a single agent in the treatment of extensive-stage small cell lung cancer.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/12/20 alle ore 05:12:31